SaNOtize to Evaluate Nitric Oxide Nasal Spray for the Treatment of Sinusitis

February 13, 2024 |

2 min read

SaNOtize Research & Development Corp., a therapeutics technology company based in Vancouver, BC, announced today the start of a Phase 2 safety and efficacy trial of its novel Nitric Oxide Nasal Spray (NONS) for the treatment of recurrent acute rhinosinusitis (RARS).

VANCOUVER, British Columbia--(BUSINESS WIRE)-- SaNOtize Research & Development Corp., a therapeutics technology company based in Vancouver, BC, announced today the start of a Phase 2 safety and efficacy trial of its novel Nitric Oxide Nasal Spray (NONS) for the treatment of recurrent acute rhinosinusitis (RARS).

SaNOtize has begun enrollment of 186 patients in a Phase 2 study in Canada that will assess the safety and efficacy of NONS compared to placebo as a treatment for RARS. The trial will focus on treating patients promptly upon the start of a sinusitis episode and will evaluate the impact of NONS treatment in accelerating the time to recovery from the sinusitis episode with symptom resolution.

Patients interested in participating in this trial, please visit this website: English, French. If shown successful, this nasal spray treatment may enable faster resolution of symptoms whenever a patient experiences a sinusitis episode and may reduce the use of antibiotics and steroids in RARS patients.

Building on the success of previous clinical studies demonstrating the effectiveness of NONS in shortening the duration of COVID-19 and reducing viral load in COVID patients, SaNOtize aims to extend the application of its nitric oxide technology to treat multiple viral and bacterial infections in the upper airways. The innovative Nitric Oxide Releasing Solution (NORS^TM) platform holds promise in offering a ground-breaking approach to treating a range of upper respiratory infections.

“Our goal in developing the SaNOtize nasal spray is to apply the well-known antimicrobial effects of nitric oxide to treat people with upper respiratory infections. With this new clinical trial, we hope to demonstrate the effectiveness of NONS against infections that induce sinusitis episodes and provide a new treatment option for sinusitis patients,” commented Steve Basta, Chief Executive Officer of SaNOtize.

About SaNOtize: SaNOtize Research & Development Corp. is a therapeutics company based in Vancouver, BC, commercializing antimicrobial products delivering nitric oxide. The company has developed and patented a Nitric Oxide Releasing Solution platform technology (NORS™) to treat and prevent upper respiratory and topical infections. For more information, visit www.SaNOtize.com. Follow us on social: LinkedIn and Twitter.